Prospective cohort study of switching from originator adalimumab (Humira) to biosimilar (Hulio) in an inflammatory bowel disease population
Latest Information Update: 07 Dec 2020
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2020 New trial record
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week